vs
Side-by-side financial comparison of AIM ImmunoTech Inc. (AIM) and PROTHENA CORP PUBLIC LTD CO (PRTA). Click either name above to swap in a different company.
PROTHENA CORP PUBLIC LTD CO is the larger business by last-quarter revenue ($21.0K vs $21.0K, roughly 1.0× AIM ImmunoTech Inc.). On growth, AIM ImmunoTech Inc. posted the faster year-over-year revenue change (-53.3% vs -99.0%). Over the past eight quarters, AIM ImmunoTech Inc.'s revenue compounded faster (-27.5% CAGR vs -35.2%).
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.
Prothena Corporation plc is a late-stage clinical biotechnology firm focused on developing and commercializing innovative antibody therapies for neurodegenerative disorders, rare diseases and immune-related conditions. Its core pipeline targets unmet medical needs including amyloidosis, Parkinson's and Alzheimer's, serving key markets across North America, Europe and the Asia-Pacific.
AIM vs PRTA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.0K | $21.0K |
| Net Profit | $-4.2M | — |
| Gross Margin | — | — |
| Operating Margin | -14057.1% | — |
| Net Margin | -19881.0% | — |
| Revenue YoY | -53.3% | -99.0% |
| Net Profit YoY | 30.0% | 62.7% |
| EPS (diluted) | $-6.46 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $21.0K | $21.0K | ||
| Q3 25 | $26.0K | $2.4M | ||
| Q2 25 | $25.0K | $4.4M | ||
| Q1 25 | $16.0K | $2.8M | ||
| Q4 24 | $45.0K | $2.1M | ||
| Q3 24 | $35.0K | $970.0K | ||
| Q2 24 | $50.0K | $132.0M | ||
| Q1 24 | $40.0K | $50.0K |
| Q4 25 | $-4.2M | — | ||
| Q3 25 | $-3.3M | $-36.5M | ||
| Q2 25 | $-2.8M | $-125.8M | ||
| Q1 25 | $-3.7M | $-60.2M | ||
| Q4 24 | $-6.0M | — | ||
| Q3 24 | $-3.7M | $-59.0M | ||
| Q2 24 | $-1.8M | $66.9M | ||
| Q1 24 | $-5.8M | $-72.2M |
| Q4 25 | -14057.1% | — | ||
| Q3 25 | -9411.5% | -1666.3% | ||
| Q2 25 | -10584.0% | -1914.4% | ||
| Q1 25 | -22618.8% | -2319.0% | ||
| Q4 24 | -13011.1% | — | ||
| Q3 24 | -12825.7% | -6857.0% | ||
| Q2 24 | -7388.0% | 44.2% | ||
| Q1 24 | -14335.0% | -163056.0% |
| Q4 25 | -19881.0% | — | ||
| Q3 25 | -12630.8% | -1513.1% | ||
| Q2 25 | -11176.0% | -2845.4% | ||
| Q1 25 | -23156.3% | -2128.5% | ||
| Q4 24 | -13260.0% | — | ||
| Q3 24 | -10571.4% | -6082.6% | ||
| Q2 24 | -3672.0% | 50.7% | ||
| Q1 24 | -14542.5% | -144478.0% |
| Q4 25 | $-6.46 | — | ||
| Q3 25 | $1.57 | $-0.68 | ||
| Q2 25 | $-3.68 | $-2.34 | ||
| Q1 25 | $-0.05 | $-1.12 | ||
| Q4 24 | $-21.80 | — | ||
| Q3 24 | $-6.00 | $-1.10 | ||
| Q2 24 | $-3.00 | $1.22 | ||
| Q1 24 | $-0.12 | $-1.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.0M | $307.5M |
| Total DebtLower is stronger | $4.5M | — |
| Stockholders' EquityBook value | $-9.8M | $280.5M |
| Total Assets | $5.8M | $326.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.0M | $307.5M | ||
| Q3 25 | $2.4M | $330.8M | ||
| Q2 25 | $835.0K | $371.4M | ||
| Q1 25 | $2.2M | $417.9M | ||
| Q4 24 | $4.0M | $471.4M | ||
| Q3 24 | $7.2M | $519.3M | ||
| Q2 24 | $10.1M | $564.1M | ||
| Q1 24 | $10.9M | $546.5M |
| Q4 25 | $4.5M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $2.7M | — | ||
| Q1 25 | $2.4M | — | ||
| Q4 24 | $2.8M | — | ||
| Q3 24 | $3.3M | — | ||
| Q2 24 | $3.3M | — | ||
| Q1 24 | $3.3M | — |
| Q4 25 | $-9.8M | $280.5M | ||
| Q3 25 | $-6.1M | $295.0M | ||
| Q2 25 | $-6.5M | $324.3M | ||
| Q1 25 | $-3.9M | $437.7M | ||
| Q4 24 | $-1.3M | $486.9M | ||
| Q3 24 | $2.9M | $534.4M | ||
| Q2 24 | $6.1M | $581.9M | ||
| Q1 24 | $4.8M | $502.4M |
| Q4 25 | $5.8M | $326.8M | ||
| Q3 25 | $5.5M | $352.6M | ||
| Q2 25 | $4.1M | $399.1M | ||
| Q1 25 | $6.2M | $495.3M | ||
| Q4 24 | $8.6M | $547.1M | ||
| Q3 24 | $13.6M | $595.3M | ||
| Q2 24 | $15.7M | $645.6M | ||
| Q1 24 | $16.2M | $623.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.13× | — | ||
| Q2 24 | 0.54× | — | ||
| Q1 24 | 0.69× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.0M | $-163.6M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.0M | $-163.6M | ||
| Q3 25 | $-5.1M | $-40.6M | ||
| Q2 25 | $-1.5M | $-46.3M | ||
| Q1 25 | $-2.4M | $-53.4M | ||
| Q4 24 | $-4.0M | $-150.1M | ||
| Q3 24 | $-3.1M | $-45.2M | ||
| Q2 24 | $-3.0M | $16.0M | ||
| Q1 24 | $-4.8M | $-73.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.24× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
